TXG (10xgenomics.com) Annual Net Income

TXG (10x Genomics) - company brandmark

The profitability of spatial biology leader 10x Genomics, Inc. (TXG) correlates directly with the funding of research centers, where consumables sales and R&D efficiency—which currently stands at -0.07—play a pivotal role. Growth is driven by biopharma behemoths transitioning to modern testing platforms. The following retrospective of TXG share prices illustrates the business dynamics of a company whose precision relies on the careful delivery of high-accuracy equipment to laboratories.

Company Net Income: 10xgenomics.com (TXG) for 07/04/2022 - 10/30/2026

Analytical breakdowns and data insights for company 10x Genomics (TXG)

- stock price and consensus target price:
Price Performance Chart 10x|TXG - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization 10x|TXG - Enterprise Value
- book value of equity indicators:
Net Asset Value per Share 10x Genomics|TXG - Company Book Value|Capitalization to Book Value Ratio 10xgenomics.com|TXG - Aggregate Company Assets
- debt burden and liquidity indicators:
Debt to Capital 10x Genomics, Inc.|TXG - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio 10x Genomics Inc|TXG - Company Aggregate Debts|Debts to Net Assets 10x|TXG - Company Long-Term Debts|Company Current Liabilities 10x Genomics|Interim Coverage Ratio 10xgenomics.com
- company profitability and valuation multiples indicators:
TXG - Net Income
Fundamental valuation:TXG - 10x
Signature product of 10x Genomics Corp

Investors utilize this indicator as the primary barometer of operational efficiency and business resilience. The metric captures the daily cash balance remaining after deducting all expenses from total revenue. By analyzing the company's income and expenditure balance, one can assess the actual speed of capital generation. For 10x Genomics, Inc. (TXG), this trend is critical due to patent wars. Technological competition in spatial biology directly impacts final margins.

Direct competitors

Tempus AI - Final Profit|QGEN (Qiagen N.V.) - Net Profit|IONS - Annual Net Income|Net Profit RGEN|RNA - Company Net Income|Company Net Income CRISPR Therapeutics Corp CRSP|WGS: Company Profit|RARE - Company Net Income|Company Net Income beamtx.com|Sarepta (SRPT) - Company Net Income|Net Income Twist Bioscience Inc|NTLA (Intellia) - Net Profit|Stoke Corp (STOK) - Net Financial Result|Net Profit BLFS|Net Income wavelifesciences.com WVE|Company Net Income Maze Therapeutics MAZE|Net Financial Result Sionna Therapeutics, Inc. (SION)|PRME: Net Income|Final Profit TSHA (Taysha Corp)|QURE: Net Profit|MGTX - Net Financial Result|Company Net Income REGENXBIO|Company Profit SLDB (Solid Biosciences Inc)|Net Profit OCGN|Net Income PacBio Corp PACB|Benitec Biopharma Inc. - Net Income|Net Financial Result designtx.com (DSGN)|RCKT: Net Income|4DMT - Profit After Payment of Taxes|LXEO (lexeotx.com) - Net Income|Company Profit KRRO|EDIT (Editas Medicine, Inc.) - Net Profit|SLN - Annual Net Income|Net Profit PRQR|codexis.com - Company Profit|Company Net Income Sangamo SGMO|NAUT: Company Profit|Metagenomi, Inc. - Net Profit|DTIL - Net Profit|GBIO: Net Profit|BOLD: Profit After Payment of Taxes|Net Income XCUR|Company Profit IMNN (Celsion Corporation)|Net Income PHIO (Phio Pharmaceuticals)|MBIO (mustangbio.com) - Final Profit|Net Profit RNAZ (TransCode Therapeutics, Inc.)|Annual Net Income Bionano Genomics Inc.|Applied DNA - Net Profit|Company Net Income bluebird bio, Inc|immunoprecise.com (IPA) - Company Net Income|Company Profit OMGA|Company Net Income Singular Genomics|Company Net Income Regulus Therapeutics, Inc. RGLS|Company Net Income Syros (SYRS)|Net Income Telesis Bio, Inc TBIO|Net Profit TCON (TRACON Pharmaceuticals)|Net Financial Result unitybiotechnology.com (UBX)